Taking 1.25 mg Mounjaro: What to Expect From the First Pen

Why the evidence points to starting at the lowest effective dose

SURMOUNT-1 enrolled 2,539 adults with obesity and no diabetes, testing tirzepatide against placebo over 72 weeks. Participants reached average body-weight reductions of around 20–21% at the 15 mg maintenance dose, figures that made headlines when the paper landed in the New England Journal of Medicine. But those results came after a careful, stepwise titration that began at doses designed to minimise early nausea, not to maximise early weight loss. That sequencing is the foundation of how the medicine is prescribed today.

The NHS tirzepatide patient information page confirms the UK licensed schedule: treatment starts at 2.5 mg for the first four weeks, then increases in 2.5 mg steps, with the prescriber deciding the pace based on tolerability. A 1.25 mg dose sits below the lowest licensed rung on that ladder, and prescribers occasionally use it in clinical practice when a patient's tolerance calls for an even gentler introduction, but it is not part of the standard SmPC schedule.

Understanding this matters because people taking 1.25 mg sometimes worry they're on the wrong dose, or that the medicine isn't working. The evidence base was built on titration, not on staying at the lowest dose indefinitely. If your prescriber has you here, there's a clinical reason, and the path forward is a conversation with them.

What your body is doing at 1.25 mg, and why the GI effects feel front and centre

Tirzepatide activates two gut-hormone receptors simultaneously: GIP and GLP-1. Even at low doses, this slows the rate at which food leaves your stomach and adjusts the appetite signals your brain receives. The effect on fullness can be noticeable earlier than most people expect. The effect on the scales is usually modest at 1.25 mg, that's by design.

What tends to be less modest is the gastrointestinal adjustment period. Nausea, looser stools, indigestion and an awareness of fullness that feels unfamiliar are all common in the first couple of weeks on a new dose. This is well documented in the SURMOUNT programme and in the SmPC. For most people, it settles. Eating smaller portions, staying well hydrated and avoiding very fatty or rich foods in these early weeks genuinely helps. You can read more about what's happening during this adjustment on our guide to taking the first dose of Mounjaro.

If nausea persists beyond two weeks, is severe, or is accompanied by sustained vomiting, contact your prescriber. Severe or persistent stomach pain that seems to reach through to your back is a sign to seek medical help promptly and report the experience via the MHRA Yellow Card scheme.

What 1.25 mg Mounjaro will not do, and when the picture changes

Here's the honest part, and it's worth saying plainly: significant weight loss at 1.25 mg is unlikely to match the results you'll see cited from the trials. The SURMOUNT evidence for meaningful body-weight reduction comes from doses of 5 mg and above, used over many months. A 1.25 mg dose is doing preparatory work, not the heavy lifting. Whether you're curious about how results differ by dose, or wondering whether some weight change is possible at this stage, the page on losing weight on 1.25 mg tirzepatide covers this question directly.

If you're on 1.25 mg and feeling impatient, that's completely understandable. Many people start treatment after months of reading about impressive trial outcomes, then find the first pen feels anticlimactic. The titration schedule exists because the alternative, jumping straight to a higher dose, produces a much harder first few weeks and is more likely to cause people to stop treatment early. The approach is evidence-led, even when it tests your patience.

For context on the full dose range and how each step fits the journey, the Mounjaro 5 mg overview gives a sense of what the next stages look like. And for a broader picture of tirzepatide and how it fits into weight management options, the Mounjaro treatment overview covers the full picture. There's also useful context on UK private treatment costs on our page about the Eli Lilly UK price change, if you're planning ahead.

Every dose increase at nume is reviewed by a real prescriber before it's approved. Our clinical team assesses each stage individually. If you haven't started yet and want to understand the full process, speaking to our prescribers is the place to begin.